Global Peripheral Neuropathy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431740
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • MORE
Peripheral Neuropathy Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global peripheral neuropathy market was valued at US$ 1,470.9s Mn in 2016, and is expected to reach US$ 1,998.8 Mn by 2025, expanding at a CAGR of 3.2% from 2017 to 2025.

Market Insights

Peripheral neuropathy mainly causes due to damage occurred to peripheral nerves resulting in weakness, numbness, and usually in hands and feet. Peripheral neuropathy is caused due to traumatic injuries, infections, metabolic problems, inherited causes and exposure to toxins, and most commonly by diabetes mellitus. According to the World Health Organization (WHO), it was estimated that there would be 285 million diabetics by 2010 in the world. This estimate is projected to increase by 65% to become 438 million in the year 2030. Thus, rising prevalence of diabetes mellitus is expected to increase the population of patients suffering from peripheral neuropathy. With a limited number of prescription drugs available for neuropathic pain, off-label prescription of several other drugs is widespread. The pharma industry has been struggling to further improve the currently available therapeutic options due to the complexity of identification of the most suitable targets for investigation. Recently, there has been a shift towards the adoption of transdermal therapies for the management of neuropathic pain.

The global peripheral neuropathy market is segmented by treatment type as pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain killers, anti-seizures medication, antidepressants. Non pharmacological therapies include transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery). Pharmacological therapies most commonly used and dominates the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options.

In the base 2016, North America was observed as the largest market for peripheral neuropathy. The rising geriatric population, growing incidences of diabetes in the region is the prime factor driving the North America peripheral neuropathy market. Asia Pacific is anticipated to be fastest growing market for the forecast period 2017-2025.

Market Competition Assessment

Key players in the global peripheral neuropathy market are Abbott Laboratories, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Merck and Co. Inc., Novartis, Pfizer Inc, Dr. Reddy's Laboratories

Key Market Movements:
  • Prediabetes and diabetes both are becoming a bigger problem and as a consequence more and more patients are anticipated to suffer from peripheral pain. As the prevalence of this condition persists to grow, the demand for treatment for peripheral neuropathy will also correspondingly increase.
  • Non-pharmacologic treatments of neuropathic pain are usually begun simultaneously with pharmacologic regimen. It is reported through various studies that reference for non-pharmacologic methods for neuropathic pain management is on a perpetual rise.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.2.1 Phase I - Secondary Research
1.2.2 Phase II - Primary Research
1.2.3 Phase III - Expert Panel Review
1.2.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Peripheral Neuropathy Market Portraiture
2.2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025, (Value %)
2.3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016, (US$ Million)

Chapter 3 Global Peripheral Neuropathy Market Analysis
3.1 Peripheral Neuropathy Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing prevalence of diabetes and cancer
3.2.1.2 Growing preference for non-pharmacological modalities
3.2.2 Challenges
3.2.2.1 Challenge of Developing New Pain Medications for Neuropathic Pain
3.2.2.2 High treatment rate as against low satisfaction indicate gap in treatment
3.2.3 Opportunities
3.2.3.1 Development of drugs with selective targeting of ion channels
3.3 Attractive Investment Proposition
3.4 Market Positioning of Key Players in Global Peripheral Neuropathy Market

Chapter 4 Global Peripheral Neuropathy Market, by Treatment Type
4.1 Overview
4.2 Pharmacological Therapies
4.2.1 Pain Relievers
4.2.1.1 Tramadol
4.2.1.2 Oxycodone
4.2.1.3 Cylcooxgenase Inhibitors
4.2.1.4 Corticosteroid
4.2.2 Anti-seizure medications
4.2.2.1 Gabapentin
4.2.2.2 Pregabalin
4.2.3 Antidepressants
4.2.3.1 Amitriptyline
4.2.3.2 Doxepin
4.2.3.3 Nortriptyline
4.2.3.4 Duloxetine
4.2.3.5 Venlafaxine
4.3 Non-Pharmacological Therapies
4.3.1 Transcutaneous electrical nerve stimulation
4.3.2 Plasma exchange and intravenous immune globulin
4.3.3 Others(Physical Therapy and Surgery)

Chapter 5 Global Peripheral Neuropathy Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia and South Africa)

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Bristol Myers Squibb
6.3 Cipla Limited
6.4 Eli Lilly and Company
6.5 GlaxoSmithKline plc.
6.6 Lupin Limited
6.7 Merck and Co. Inc.
6.8 Novartis
6.9 Pfizer Inc.
6.10 Dr. Reddy's Laboratories

List of Figures
Fig. 1 Global Peripheral Neuropathy Market: Research Methodology
Fig. 2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025 (Value %)
Fig. 3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016 (US$ Million)
Fig. 4 Attractive Investment Proposition: Global Peripheral Neuropathy Market, by Region
Fig. 5 Market Positioning of Key Players: Global Peripheral Neuropathy Market
Fig. 6 Tramadol Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 7 Oxycodone Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 8 Cylcooxgenase Inhibitors Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 9 Corticosteroid Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 10 Gabapentin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 11 Pregabalin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 12 Amitriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 13 Doxepin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 14 Nortriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 15 Duloxetine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 16 Venlafaxine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 17 Transcutaneous Electrical Nerve Stimulation Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 18 Plasma Exchange and Intravenous Immune Globulin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 19 Others (Physical Therapy and Surgery) Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
Fig. 20 Latin America Peripheral Neuropathy Market, 2015 - 2025 (US$ Mn)
Fig. 21 Middle East & Africa Peripheral Neuropathy Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Peripheral Neuropathy Market, by Treatment Type, 2015 - 2025 (US$ Mn)
Table 2 Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 - 2025 (US$ Mn)
Table 3 Pain Relievers Global Peripheral Neuropathy Market, 2015 - 2025 (US$ Mn)
Table 4 Anti-seizure Medications Global Peripheral Neuropathy Market, 2015 - 2025 (US$ Mn)
Table 5 Antidepressant Global Peripheral Neuropathy Market, 2015 - 2025 (US$ Mn)
Table 6 Non- Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 - 2025 (US$ Mn)
Table 7 Global Peripheral Neuropathy Market, by Region, 2015 - 2025 (US$ Mn)
Table 8 North America Peripheral Neuropathy Market, by Country, 2015 - 2025 (US$ Mn)
Table 9 Europe Peripheral Neuropathy Market, by Country, 2015 - 2025 (US$ Mn)
Table 10 Asia-Pacific Peripheral Neuropathy Market, by Country, 2015 - 2025 (US$ Mn)
Table 11 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 12 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 13 Cipla Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 14 Eli Lilly and Company: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 15 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 16 Lupin Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 17 Merck and Co. Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 18 Novartis: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 19 Pfizer Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 20 Dr. Reddy's Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories
  • Bristol Myers Squibb
  • Cipla Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Lupin Limited
  • Merck and Co. Inc.
  • Novartis
  • Pfizer Inc.
  • Dr. Reddy's Laboratories
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll